UBS Group
NRSN icon

UBS Group’s NeuroSense Therapeutics NRSN Stock Holding History

UBS Group’s Portfolio NRSN Stock Details NRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$78.2K Buy
5,432
+2,977
+121% +$46.4K ﹤0.01% 7320
2026
Q1 		$37.1K Buy
2,455
+911
+59% +$16.3K ﹤0.01% 7557
2025
Q4 		$23.7K Buy
1,544
+811
+111% +$17.1K ﹤0.01% 7666
2025
Q3 		$18.3K Buy
733
+652
+805% +$19.1K ﹤0.01% 8210
2025
Q2 		$3.04K Sell
81
-33
-29% -$956 ﹤0.01% 9391
2025
Q1 		$2.12K Buy
+114
New +$2.52K ﹤0.01% 9386
2024
Q2 		– Sell
-596
Closed -$21.7K – 9920
2024
Q1 		$21.7K Buy
596
+321
+117% +$8.64K ﹤0.01% 6892
2023
Q4 		$4.31K Sell
275
-208
-43% -$2.77K ﹤0.01% 7877
2023
Q3 		$6.86K Buy
+483
New +$10.1K ﹤0.01% 7266
2023
Q2 		– Sell
-238
Closed -$8.19K – 9407
2023
Q1 		$8.19K Buy
238
+35
+17% +$1.16K ﹤0.01% 7748
2022
Q4 		$4.96K Buy
203
+112
+123% +$3.56K ﹤0.01% 9238
2022
Q3 		$3K Sell
91
-580
-86% -$23.8K ﹤0.01% 9562
2022
Q2 		$45K Buy
671
+577
+614% +$21.9K ﹤0.01% 6003
2022
Q1 		$7K Sell
94
-307
-77% -$14.6K ﹤0.01% 8829
2021
Q4 		$20K Buy
+401
New +$24.4K ﹤0.01% 7843

Other funds holding NRSN

IAA
Independent Advisor Alliance Charlotte, North Carolina $4.27B AUM 45.92% 1-Year Est. Return
YAG
Yorkville Advisors Global Mountainside, New Jersey $86.2M AUM 41.28% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $202B AUM 37.79% 1-Year Est. Return
Pathstone Holdings
Pathstone Holdings Englewood, New Jersey $34.3B AUM 27.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $171B AUM 24.68% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
Jones Financial Companies
Jones Financial Companies Des Peres, Missouri $250B AUM 21.32% 1-Year Est. Return

UBS Group's NRSN Position: Q2 2026 in Review

UBS Group increased its NeuroSense Therapeutics (NRSN) stake by 121% in Q2 2026, buying an estimated $46.4K and bringing the position to 5,432 shares worth $78.2K. The position accounts for ﹤0.01% of the portfolio, ranked #7320.

UBS Group first reported a position in NRSN in Q4 2021 and has held it in 15 quarters since. 12 funds tracked by Wall St. Rank hold NRSN as of Q2 2026.

  • UBS Group held 5,432 shares of NeuroSense Therapeutics worth $78.2K as of Q2 2026.
  • UBS Group bought 2,977 NeuroSense Therapeutics shares in Q2 2026, an estimated $46.4K.
  • NeuroSense Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #7320 holding.
  • UBS Group first reported a position in NeuroSense Therapeutics in Q4 2021 and has held it in 15 quarters since.
  • 12 funds tracked by Wall St. Rank held NeuroSense Therapeutics as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.